EPHA2 and cancer: Several EphA2-specific T cells have been developed and evaluated in preclinical studies, recognizing EphA2-expressing tumors as assessed by interferon-γ (IFN-γ) and IL-2 synthesis and conferring cancer cell cytotoxicity.